ketorolac has been researched along with Uveitis, Anterior in 5 studies
Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)
ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.
5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.
Uveitis, Anterior: Inflammation of the anterior uvea comprising the iris, angle structures, and the ciliary body. Manifestations of this disorder include ciliary injection, exudation into the anterior chamber, iris changes, and adhesions between the iris and lens (posterior synechiae). Intraocular pressure may be increased or reduced.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report the antiinflammatory effect and efficacy of preoperative treatment with ketorolac in a patient with rheumatoid arthritis having phacoemulsification." | 3.71 | Antiinflammatory effect of preoperative ketorolac in phacoemulsification. ( Caronia, RM; Donnenfeld, ED; Perry, HD, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kiyat, P | 1 |
| Palamar, M | 1 |
| Yilmaz, SG | 1 |
| Emre, S | 1 |
| Ganapathy, PS | 1 |
| Lowder, CY | 1 |
| Srivastava, SK | 1 |
| Tan, TE | 1 |
| Cheung, CM | 1 |
| Mehta, JS | 1 |
| Donnenfeld, ED | 2 |
| Nichamin, LD | 1 |
| Hardten, DR | 1 |
| Raizman, MB | 1 |
| Trattler, W | 1 |
| Rajpal, RK | 1 |
| Alpern, LM | 1 |
| Felix, C | 1 |
| Bradford, RR | 1 |
| Villanueva, L | 1 |
| Hollander, DA | 1 |
| Schiffman, RM | 1 |
| Caronia, RM | 1 |
| Perry, HD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00521456] | Phase 3 | 263 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| [NCT00524264] | Phase 3 | 248 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Pupil area post-irrigation and aspiration (NCT00521456)
Timeframe: Day 0
| Intervention | millimeters squared (mm²) (Mean) |
|---|---|
| Ketorolac Solution | 37.9 |
| Vehicle Solution | 36.5 |
Measured on a scale of 0-4 (0 = none, 4 = intolerable) (NCT00521456)
Timeframe: Day 1
| Intervention | % of participants with a score of 0 (Number) |
|---|---|
| Ketorolac Solution | 70.0 |
| Vehicle Solution | 38.5 |
Anterior chamber inflammation is the sum of biomicroscopic cell and flare; each measured on a scale of 0-4 (Flare: 0 = no flare, 4 = intense flare / Cell: 0 = no cells, 4 = >50 cells) (NCT00521456)
Timeframe: Day 14
| Intervention | % of participants with a score of 0 (Number) |
|---|---|
| Ketorolac Solution | 58.0 |
| Vehicle Solution | 27.3 |
Patients with ≥ 3 line improvement in visual acuity (NCT00521456)
Timeframe: Change from baseline at Day 14
| Intervention | Percentage of patients with ≥ 3 lines (Number) |
|---|---|
| Ketorolac Solution | 56.9 |
| Vehicle Solution | 36.3 |
Pupil area post-irrigation and aspiration (NCT00524264)
Timeframe: Day 0
| Intervention | millimeters squared (mm²) (Mean) |
|---|---|
| Ketorolac Solution | 41.8 |
| Vehicle Solution | 41.1 |
Measured on a scale of 0-4 (0 = none, 4 = intolerable) (NCT00524264)
Timeframe: Day 1
| Intervention | % of participants with a score of 0 (Number) |
|---|---|
| Ketorolac Solution | 75.0 |
| Vehicle Solution | 41.0 |
Anterior chamber inflammation is the sum of biomicroscopic cell and flare; each measured on a scale of 0-4 (Flare: 0 = no flare, 4 = intense flare / Cell: 0 = no cells, 4 = >50 cells) (NCT00524264)
Timeframe: Day 14
| Intervention | % of participants with a score of 0 (Number) |
|---|---|
| Ketorolac Solution | 46.3 |
| Vehicle Solution | 25.6 |
Patients with ≥ 3 line improvement in visual acuity (NCT00524264)
Timeframe: Change from baseline at Day 14
| Intervention | Percentage of patients with ≥ 3 lines (Number) |
|---|---|
| Ketorolac Solution | 59.5 |
| Vehicle Solution | 46.2 |
1 trial available for ketorolac and Uveitis, Anterior
| Article | Year |
|---|---|
Twice-daily, preservative-free ketorolac 0.45% for treatment of inflammation and pain after cataract surgery.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Eye Pa | 2011 |
Twice-daily, preservative-free ketorolac 0.45% for treatment of inflammation and pain after cataract surgery.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Eye Pa | 2011 |
Twice-daily, preservative-free ketorolac 0.45% for treatment of inflammation and pain after cataract surgery.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Eye Pa | 2011 |
Twice-daily, preservative-free ketorolac 0.45% for treatment of inflammation and pain after cataract surgery.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Eye Pa | 2011 |
4 other studies available for ketorolac and Uveitis, Anterior
| Article | Year |
|---|---|
Correlation between corneal involvement and anterior chamber flare in epidemic keratoconjunctivitis.
Topics: Adenovirus Infections, Human; Adolescent; Adult; Aged; Anterior Chamber; Anti-Inflammatory Agents, N | 2020 |
Aggressive Initial Presentation of HLA-B27 Uveitis in Older Individuals: A Case Series.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Female; Glucocorticoids; HLA-B27 A | 2018 |
Activation of Cytomegalovirus corneal endotheliitis following laser in situ keratomileusis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Aqueous Humor; Cytomegalovirus; Cy | 2016 |
Antiinflammatory effect of preoperative ketorolac in phacoemulsification.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cataract; Drug Therapy, Combin | 2002 |